Evaluation of Drug "X" in Preclinical Models of Parkinson's Disease

Evaluation of Drug "X" in Preclinical Models of Parkinson's Disease

Parkinson's disease (PD) is a hypokinetic, age-related movement disorder associated with chronic, progressive degeneration of dopaminergic neurons, with cell bodies located in the substantia nigra pars compacta (SNpc) and axon terminals in the striatum. Striatal depletion of the neurotransmi...

Full description

Bibliographic Details
Main Author:	Samtani, Grace
Other Authors:	Falk, Torsten
Language:	en_US
Published:	The University of Arizona. 2017
Online Access:	http://hdl.handle.net/10150/625144 http://arizona.openrepository.com/arizona/handle/10150/625144

Similar Items

Preclinical Modeling of Treatment-induced Impulsivity in Parkinson's Disease
by: Aleksandrova, Lily R
Published: (2013)

Preclinical Modeling of Treatment-induced Impulsivity in Parkinson's Disease
by: Aleksandrova, Lily R
Published: (2013)

Sleep and circadian rhythms in Parkinson’s disease and preclinical models
by: Coulson, E.J, et al.
Published: (2022)

Achieving the next level of Growth through Competitive Intelligence Practices: An Exploratory Study of Romanian
by: Mukta SAMTANI, et al.
Published: (2012-12-01)

Designing Growth Strategies for Romanian Offshore Outsourcing Vendors: Deploying Competitive Intelligence from Indian Software Industry
by: Mukta SAMTANI, et al.
Published: (2012-11-01)

Advantages of nonhuman primates as preclinical models for evaluating stem cell-based therapies for Parkinson's disease
by: Douglas A. Grow, et al.
Published: (2016-09-01)

Mitochondrial Dynamics and Mitophagy in the 6-Hydroxydopamine Preclinical Model of Parkinson's Disease
by: Maria F. Galindo, et al.
Published: (2012-01-01)

Optimasi Tarif Kereta Bandara Soekarno-Hatta dengan Model Permintaan Berbasis Discrete Choice Experiment
by: Fransiscus Rian Pratikto, et al.
Published: (2021-04-01)

Circuit imaging biomarkers in preclinical and prodromal Parkinson's disease
by: Sanne K. Meles, et al.
Published: (2021-09-01)

Enhanced Neuroprotective Effects of Coadministration of Tetrandrine with Glutathione in Preclinical Model of Parkinson’s Disease
by: Xiang-Yun Li, et al.
Published: (2015-01-01)

Are Parkinson’s Disease Patients the Ideal Preclinical Population for Alzheimer’s Disease Therapeutics?
by: Thomas F. Tropea, et al.
Published: (2021-08-01)

Molecular Markers of Alzheimer’s and Parkinson’s Diseases
by: Cooper, Grace
Published: (2018)

Disease progression model for Clinical Dementia Rating–Sum of Boxes in mild cognitive impairment and Alzheimer’s subjects from the Alzheimer’s Disease Neuroimaging Initiative
by: Samtani MN, et al.
Published: (2014-05-01)

Neuroprotective Surgical Strategies in Parkinson’s Disease: Role of Preclinical Data
by: Napoleon Torres, et al.
Published: (2017-10-01)

The Preclinical Research Progress of Stem Cells Therapy in Parkinson’s Disease
by: Jun Zhang, et al.
Published: (2016-01-01)

Level of endosulfan among women in Talwandi Sabo Block of Southern Punjab, India
by: Noopur Sharma, et al.
Published: (2019-01-01)

Micromethod for PMN function studies in neonates.
by: Samtani J, et al.
Published: (1991-07-01)

Outcomes of Sepsis and Septic Shock in Cancer Patients: Focus on Lactate
by: René López, et al.
Published: (2021-04-01)

α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson’s disease
by: Cecilia S. Lindestam Arlehamn, et al.
Published: (2020-04-01)

Estimating economic efficiency of preclinical diagnostics of Parkinson disease with cost-utility approach
by: Irina A. Denisova, et al.
Published: (2020-12-01)

A Preclinical Systematic Review of Ginsenoside-Rg1 in Experimental Parkinson’s Disease
by: Liang Song, et al.
Published: (2017-01-01)

Dopamine transporter neuroimaging accurately assesses the maturation of dopamine neurons in a preclinical model of Parkinson’s disease
by: Julian L. Goggi, et al.
Published: (2020-08-01)

Do Compensatory Processes Underlie the Preclinical Phase of Neurodegenerative Disease? Insights from an Animal Model of Parkinsonism
by: Michael J. Zigmond
Published: (1997-01-01)

The basics of preclinical drug development for neurodegenerative disease indications
by: Spack Edward G, et al.
Published: (2009-06-01)

Flavonoids as Therapeutic Agents in Alzheimer’s and Parkinson’s Diseases: A Systematic Review of Preclinical Evidences
by: Roxana Braga de Andrade Teles, et al.
Published: (2018-01-01)

Comment on “A Preclinical Systematic Review of Ginsenoside-Rg1 in Experimental Parkinson’s Disease”
by: Yi-bo He, et al.
Published: (2017-01-01)

Behavioral phenotyping of Parkin-deficient mice: looking for early preclinical features of Parkinson's disease.
by: Daniel Rial, et al.
Published: (2014-01-01)

Preclinical Comparison of Stem Cells Secretome and Levodopa Application in a 6-Hydroxydopamine Rat Model of Parkinson’s Disease
by: Fábio G. Teixeira, et al.
Published: (2020-01-01)

hESC-Derived Dopaminergic Transplants Integrate into Basal Ganglia Circuitry in a Preclinical Model of Parkinson’s Disease
by: Andrew F. Adler, et al.
Published: (2019-09-01)

Parkinson′s disease
by: Behari Madhuri, et al.
Published: (2011-01-01)

Pain in Parkinson's disease Dor na doença de Parkinson
by: Grace Helena Letro, et al.
Published: (2009-09-01)

Advances and Research Directions in Data-Warehousing Technology
by: Mukesh Mohania, et al.
Published: (1999-11-01)

Dissecting the Molecular Function of Triticum aestivum STI Family Members Under Heat Stress
by: Shaloo Meena, et al.
Published: (2020-08-01)

Mathematical Relationship Between Particle Reynolds Number and Ripple Factor using Tapi River Data, India.
by: S. M. Yadav, et al.
Published: (2011-02-01)

Preclinical and clinical issues in Alzheimer’s disease drug research and development.
by: Cesare eMancuso, et al.
Published: (2014-10-01)

Preclinical and clinical issues in Alzheimer's disease drug research and development
Published: (2015)

Evaluation of models of Parkinson’s Disease
by: Shail Adrian Jagmag, et al.
Published: (2016-01-01)

Preclinical experimental models of drug metabolism and disposition in drug discovery and development
by: Donglu Zhang, et al.
Published: (2012-12-01)

Preclinical pharmacokinetic evaluation of novel antimalarial and antituberculosis drug leads
by: Strydom, Natasha
Published: (2019)

Spinal cord stimulation in Parkinson’s disease: a review of the preclinical and clinical data and future prospects
by: Yi Cai, et al.
Published: (2020-03-01)